Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Journal article

BACKGROUND: For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years. METHODS: In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12,894 women with early breast cancer who had completed 5 years of treatment with tamo...

Expand abstract

Authors: Davies, C; Pan, H; Godwin, J; Gray, R; Arriagada, R

• Publication status: Published
• Journal: Lancet (London, England)
• Volume: 381
• Issue: 9869
• Pages: 805-816
• Publication date: 2013-03-01
• DOI: 10.1016/s0140-6736(12)61963-1
• EISSN: 1474-547X
• ISSN: 0140-6736
• Language: English
• Keywords: Chemotherapy, Adjuvant; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group; Antineoplastic Agents, Hormonal; Aged; Humans; Adult; Female; Tamoxifen; Middle Aged; Breast Neoplasms; Time Factors; Receptors, Estrogen